HTR4
MOLECULAR TARGET5-hydroxytryptamine receptor 4
HTR4 (5-hydroxytryptamine receptor 4) is targeted by 9 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting HTR4
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Metoclopramide | 2.20 | 8 |
| 2 | Mescaline Hallucinogenic alkaloid isolated from | 1.10 | 2 |
| 3 | Pergolide | 1.10 | 2 |
| 4 | Mianserin | 0.69 | 1 |
| 5 | Amitriptyline Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent | 0.69 | 1 |
| 6 | Cyproheptadine | 0.69 | 1 |
| 7 | Metergoline | 0.69 | 1 |
| 8 | Nortriptyline | 0.69 | 1 |
| 9 | Ondansetron | 0.69 | 1 |
About HTR4 as a Drug Target
HTR4 (5-hydroxytryptamine receptor 4) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 9 compounds with documented HTR4 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
HTR4 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.